Lv3
350 积分 2021-09-11 加入
FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004)
2天前
已完结
Adherence to community-based lung cancer screening in the Yorkshire Lung Screening Trial
10天前
已完结
A study of high dose furmonertinib in EGFR exon 20 insertion mutation-positive advanced non-small cell lung cancer
10个月前
已完结
Practical Management of Oligometastatic Non–Small-Cell Lung Cancer
1年前
已完结
Comprehensive kinomic study via a chemical proteomic approach reveals kinome reprogramming in hepatocellular carcinoma tissues
1年前
已完结
Elevated NOX4 promotes tumorigenesis and acquired EGFR-TKIs resistance via enhancing IL-8/PD-L1 signaling in NSCLC
1年前
已完结
EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study
2年前
已完结
Phase 2 study of tarloxotinib bromide (TRLX) in patients (pts) with EGFR-Mutant, T790M-Negative NSCLC progressing on an EGFR TKI
2年前
已关闭
Abstract A157: Antitumor activity of tarloxotinib, a hypoxia-activated EGFR TKI, in patient-derived lung cancer cell lines harboring EGFR exon 20 insertions
2年前
已关闭
Targeting EGFR Exon 20 Insertions in Non–Small Cell Lung Cancer: Recent Advances and Clinical Updates
2年前
已完结
皖公网安备34019202002308
